Want to see IN:SYNCOMF full AI Analyst Report?

Syncom Formulation (India) Ltd. (SYNCOMF) Price & Analysis

6 Followers

SYNCOMF Stock Chart & Stats

₹15.88

₹0.19(1.32%)

At close: Aug 11 4:00 PM EDT

₹15.88

₹0.19(1.32%)

Day’s Range― - ―

52-Week Range₹10.21 - ₹27.53

Previous CloseN/A

Volume4.93M

Average Volume (3M)1.14M

Market Cap

₹24.74B

Enterprise Value₹8.57K

Total Cash (Recent Filing)₹1.13B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)27.6

Beta1.53

Next Earnings

Nov 16, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.4%

Share Statistics

EPS (TTM)0.91

Shares Outstanding940,000,000

10 Day Avg. Volume1,004,930

30 Day Avg. Volume1,138,778

Financial Highlights & Ratios

PEG Ratio0.30

Price to Book (P/B)2.34

Price to Sales (P/S)1.99

P/FCF Ratio21.48

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Sharply De-levered Balance SheetThe steep reduction in debt materially improves solvency and lowers financial pressure, giving Syncom greater flexibility to fund operations and growth. Expanded equity of about ₹4.15B further strengthens the balance sheet and makes the business more resilient to operating volatility.

Improved ProfitabilityThe substantial improvement in net margin indicates stronger recent earnings power and provides more internal resources for investment, debt avoidance, and shareholder returns. Maintaining solid operating profitability would support durable performance even if revenue growth remains uneven.

Rebound In Free Cash FlowThe strong FY2026 cash-flow rebound shows that the company can convert a meaningful portion of earnings into funds available for reinvestment or financial strengthening. This supports self-funded growth and reduces reliance on external financing, particularly alongside very low leverage.

Bears Say

FY2026 Revenue DeclineThe return to revenue contraction after two years of scale expansion raises questions about the consistency of demand, product volumes, or market execution. If the decline persists, it could limit operating leverage and make recent profitability improvements harder to sustain.

Gross Margin CompressionA reduction of roughly seven percentage points in gross margin weakens the earnings buffer available to absorb costs and fund growth. Unless pricing, product mix, or input-cost pressures improve, future revenue may contribute less profit and constrain margin sustainability.

Uneven Cash-Flow ConversionAlthough cash generation improved sharply in FY2026, the multi-year pattern remains inconsistent relative to reported profits. Uneven conversion can complicate planning and reduce confidence that accounting earnings will consistently translate into funds for investment, distributions, or balance-sheet support.

Syncom Formulation (India) Ltd. News

Syncom Formulations Sets Dividend Record Date and Offers Waiver Option Ahead of Virtual AGM

Syncom Formulation (India) Ltd. ( ($IN:SYNCOMF) ) has shared an update. Syncom Formulations (India) Ltd. has set 23...

14d ago

Syncom Formulations Promoters File Annual SEBI SAST Shareholding Disclosure

Syncom Formulation (India) Ltd. ( ($IN:SYNCOMF) ) has provided an announcement. Syncom Formulations (India) Ltd. has reported that...

6M ago

Syncom Formulations Faces Rs 1.42 Crore GST Demand and Penalty After Appeal Rejection

Syncom Formulation (India) Ltd. ( ($IN:SYNCOMF) ) has provided an update. Syncom Formulations (India) Ltd. has disclosed that...

9M ago

Syncom Formulations Acquires Strategic Commercial Property in Mumbai

An announcement from Syncom Formulation (India) Ltd. ( ($IN:SYNCOMF) ) is now available. Syncom Formulations (India) Limited has...

10M ago

Syncom Formulations Appoints New Secretarial Auditor

Syncom Formulation (India) Ltd. ( ($IN:SYNCOMF) ) has shared an announcement. Syncom Formulations (India) Limited has announced a...

1y ago

Syncom Formulations Announces 37th AGM and Key Appointments

Syncom Formulation (India) Ltd. ( ($IN:SYNCOMF) ) has provided an update. Syncom Formulations (India) Limited has announced its...

1y ago

SYNCOMF FAQ

What was Syncom Formulation (India) Ltd.’s price range in the past 12 months?

Syncom Formulation (India) Ltd. lowest stock price was ₹10.21 and its highest was ₹27.53 in the past 12 months.

What is Syncom Formulation (India) Ltd.’s market cap?

Syncom Formulation (India) Ltd.’s market cap is ₹24.74B.

When is Syncom Formulation (India) Ltd.’s upcoming earnings report date?

Syncom Formulation (India) Ltd.’s upcoming earnings report date is Nov 16, 2026 which is in 46 days.

How were Syncom Formulation (India) Ltd.’s earnings last quarter?

Syncom Formulation (India) Ltd. released its earnings results on Aug 11, 2026. The company reported ₹0.264 earnings per share for the quarter.

Is Syncom Formulation (India) Ltd. overvalued?

According to Wall Street analysts Syncom Formulation (India) Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Syncom Formulation (India) Ltd. pay dividends?

Syncom Formulation (India) Ltd. pays a Notavailable dividend of ₹0.1 which represents an annual dividend yield of 0.4%. See more information on Syncom Formulation (India) Ltd. dividends here

What is Syncom Formulation (India) Ltd.’s EPS estimate?

Syncom Formulation (India) Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Syncom Formulation (India) Ltd. have?

Syncom Formulation (India) Ltd. has 940,000,000 shares outstanding.

What happened to Syncom Formulation (India) Ltd.’s price movement after its last earnings report?

Syncom Formulation (India) Ltd. reported an EPS of ₹0.264 in its last earnings report. Following the earnings report the stock price went up 0.97%.

Which hedge fund is a major shareholder of Syncom Formulation (India) Ltd.?

Currently, no hedge funds are holding shares in IN:SYNCOMF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Syncom Formulation (India) Ltd.

Established in 1985 and based in Indore, India, Syncom Formulations (India) Limited specializes in the development, marketing, and sale of a wide array of finished pharmaceutical products. The company provides an extensive portfolio addressing numerous therapeutic categories, including but not limited to pain relief, infectious diseases, cardiovascular health, mental well-being, respiratory ailments, and nutritional deficiencies, alongside specific treatments for conditions like gout and erectile dysfunction, encompassing both generic and specialized medicines. These medicinal preparations are available in various formats such as tablets, capsules, oral liquids, injectables (both liquid and dry vial), dry syrups, topical ointments, inhalers, and herbal formulations. In addition to its core pharmaceutical business, Syncom Formulations also engages in commodity trading and property leasing. The company serves the domestic Indian market and actively exports its products globally.